Latest Conference Articles

March 7th 2021, 3:07pm

PER® Miami Breast Cancer Conference

A wave of approvals and a rapidly evolving treatment landscape could make the next decade a watershed period in breast cancer care.

March 6th 2021, 8:36pm

PER® Miami Breast Cancer Conference

Even in 2021, disparities in outcomes of younger women with breast cancer vs their older counterparts remain; addressing behavioral issues and psychological concerns in this population could vastly improve their quality of life, treatment adherence, and ultimately, survival.

March 6th 2021, 7:30pm

PER® Miami Breast Cancer Conference

Off Our Chests: A Candid Tour Through the World of Cancer is a memoir that dives into Liza Marshall’s breast cancer journey.

March 6th 2021, 7:25pm

PER® Miami Breast Cancer Conference

Although phase 3 data suggest that the addition of checkpoint inhibitors to neoadjuvant chemotherapy could improve pathologic complete response rates for patients with early-stage triple-negative breast cancer, immature data and the risk of long-term toxicity indicate that the therapy is not ready for primetime

March 6th 2021, 7:11pm

PER® Miami Breast Cancer Conference

Kevin Kalinsky, MD, MS, discusses the potential of antibody-drug conjugates across breast cancer subtypes.

March 6th 2021, 6:55pm

PER® Miami Breast Cancer Conference

Hope S. Rugo, MD, discusses the benefit of margetuximab-cmkb in patients with HER2-positive breast cancer who have received prior HER2-targeted therapies.

March 6th 2021, 5:47pm

PER® Miami Breast Cancer Conference

The introduction of new therapies for patients with recurrent HER2-positive metastatic breast cancer has resulted in a crowded landscape for third-line treatments and beyond, raising questions about how best to sequence a wealth of options.

March 6th 2021, 5:18pm

PER® Miami Breast Cancer Conference

Targeted agents and chemotherapy regimens are at the crux of systemic research efforts focused on improving outcomes for patients with breast cancer who have brain metastases and/or leptomeningeal disease.

March 5th 2021, 10:46pm

PER® Miami Breast Cancer Conference

Debu Tripathy, MD, discusses efforts being made to minimize the risk of disease recurrence in patients with early-stage HER2-positive breast cancer.

March 5th 2021, 10:37pm

PER® Miami Breast Cancer Conference

Olufunmilayo Falusi Olopade, MD, FACP, discusses racial disparities in breast cancer outcomes.

March 5th 2021, 9:30pm

PER® Miami Breast Cancer Conference

With the identification of numerous molecular abnormalities that can affect treatment and the course of disease in patients with breast cancer, it’s become understood that genetic profiling can define clinical trial eligibility, the presence or absence of aberrations help to drive treatment decisions, and variants can be predictive for response or resistance.

March 5th 2021, 9:26pm

PER® Miami Breast Cancer Conference

Although there is evidence to suggest that surgery with or without radiation therapy can be utilized in some patients with stage IV breast cancer who have experienced locoregional progression or symptoms to some success with regard to locoregional disease control, most patients will not achieve a survival benefit.

March 5th 2021, 7:42pm

PER® Miami Breast Cancer Conference

CDK4/6 inhibitors plus aromatase inhibitors have shown benefit as frontline treatment for patients with hormone receptor–positive, HER2-negative advanced breast cancer, but more data are needed to determine their role as adjuvant therapy before they are adopted into standard practice for patients with early-stage disease.

March 5th 2021, 3:08am

PER® Miami Breast Cancer Conference

Adam M. Brufsky, MD, PhD, discusses the role of neoadjuvant chemotherapy in triple-negative breast cancer.

March 5th 2021, 2:52am

PER® Miami Breast Cancer Conference

Patrick I. Borgen, MD, discusses eliminating the use of opioids in patients with breast cancer.

March 2nd 2021, 9:35pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Genomic sequencing is a critical step in informing the prognosis of patients with acute lymphoblastic leukemia and more information regarding specific subgroups of ALL, such as lineage ambiguous ALL, could pave the way for more personalized therapies for patients.

March 2nd 2021, 9:25pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Although it is too soon to tell whether the addition of a CD20-directed antibody to novel agents in relapsed/refractory follicular lymphoma should become standard practice, it is clear that immunotherapy could represent the next paradigm shift.

March 2nd 2021, 9:03pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

With an increased understanding of disease biology, several approaches are under examination to optimize the management of patients with graft-versus-host disease.

March 2nd 2021, 12:13am

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Minimal residual disease has helped to predict relapse in numerous leukemia subtypes, with novel testing methods helping to identify the biomarker at a higher sensitivity than ever before.

March 1st 2021, 11:22pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

The treatment landscape of Waldenström macroglobulinemia is becoming increasingly complex with second-generation BTK inhibitors; however, the combination of bendamustine and rituximab remains the frontline standard of care for this patient population.